Clinical trial tag: Rucaparib

 

An ovarian cancer researching looking into a microscope
Closed trial

Centurion: a trial looking at rucaparib with immunotherapy in relapsed ovarian cancer

The purpose of this trial is to find out how safe and effective it is to have either one or two immunotherapy drugs alongside the parp inhibitor Rucaparib. Researchers want to find out if using the different combination of drugs will prolong the time it takes for your cancer to come back compared with being treated with Rucaparib on its own. The…

A woman talks to her husband whilst having chemotherapy
Closed trial

ATHENA: A trial using a PARP inhibitor and anti-PD-1 inhibitor to prevent recurrence

Maintenance treatment refers to drugs that are given to try to slow or prevent or delay the cancer's return after it has responded to chemotherapy. Currently the PARP inhibitors (one of which is rucaparib) are the only type of targeted treatment licensed for maintenance use in ovarian cancer in the UK. Nivolumab is a different type of targeted t…

A woman with ovarian cancer wearing a coat and green jumper walking down a hospital corridor
Closed trial

ARIEL 4: A study of rucaparib or chemotherapy in BRCA positive ovarian cancer

In this trial, the researchers are trying to find out whether it's safe and effective to use a PARP inhibitor rather than standard chemotherapy in women with a BRCA gene mutation who've had two previous chemotherapy treatments. The drugs involved in this trial: Rucaparib – a targeted treatment known as a PARP inhibitor Paclitaxel – a sta…